Tirzepatide

Tirzepatide is a novel medication approved by the US Food and Drug Administration (FDA) for treating type 2 diabetes mellitus (T2DM). This medication also demonstrates efficacy in weight loss, leading to its off-label use for obesity treatment. Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide.

Tirzepatide is currently utilized as a second-line diabetes medication akin to GLP-1 drugs, such as semaglutide, and is administered once weekly via subcutaneous injection with incremental dosage adjustments. Tirzepatide is not approved for the treatment of type 1 diabetes mellitus (T1DM) and has not undergone studies in patients with pancreatitis. The most commonly reported adverse effects of the drug are gastrointestinal, including nausea, vomiting, and diarrhea. This activity provides an overview of the indications, mechanism of action, adverse effects, contraindications, and important considerations for using tirzepatide. This activity also aids clinicians in gaining proficiency in administering tirzepatide and managing T2DM in patients, thereby enhancing overall outcomes in patient care and safety.

Objectives:

• Identify appropriate candidates for tirzepatide therapy based on their clinical profile and treatment goals.
• Assess patient response to tirzepatide therapy by regularly monitoring glycemic control and weight changes.
• Select optimal combination therapies or alternative treatment options for patients with complex medical histories or treatment-resistant diabetes.
• Collaborate with interdisciplinary healthcare teams to coordinate care transitions and follow-up appointments to facilitate continuity of tirzepatide therapy and monitor long-term outcomes.

Access free multiple choice questions on this topic.

Indications

FDA-Approved Indications

Tirzepatide is a novel medication approved by the US Food and Drug Administration (FDA) in May 2022 for treating type 2 diabetes mellitus (T2DM). Tirzepatide is a synthetic polypeptide and dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Therefore, the drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide.[1]

Tirzepatide is currently utilized as a second-line diabetes medication akin to GLP-1 drugs, such as semaglutide, and is administered once weekly via subcutaneous (SQ) injection with incremental dosage adjustments.[2]

Current clinical data demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1c (HbA1c) levels. The SURPASS-5 clinical trial showed a -2.11% reduction in HbA1c levels at 5 mg per week dosing, compared to -0.86% with a placebo. At the highest dose of 15 mg per week, tirzepatide led to a -2.34% reduction in HbA1c. This was demonstrated over 40 weeks. A weight reduction of 5.4 kg was seen with 5 mg of tirzepatide dosing, and a 10.5 kg reduction was observed with 15 mg dosing. This dose-dependent correlation with weight loss is similar to semaglutide—a common GLP-1 medication utilized for weight loss management.[3]

The results of the SURPASS trials demonstrate that tirzepatide yields clinically significant improvements in glycemic control and weight loss when compared with other GLP-1 receptor agonists (semaglutide and dulaglutide), insulin degludec, and insulin glargine. Consequently, the American Diabetes Association (ADA) categorizes tirzepatide as a highly effective therapy for achieving glycemic control and weight loss.[4][5]

Comparatively, tirzepatide works similarly to GLP-1 medications but with greater efficacy. Given the weight loss properties and lack of liver toxicity,[6] it is likely to have an indirect role in the treatment of nonalcoholic fatty liver disease. However, further research is needed before the use is approved for metabolic dysfunction-associated steatotic liver disease.[7]

Off-Label Uses

Tirzepatide is not approved for the treatment of type 1 diabetes mellitus (T1DM) and has not undergone studies in patients with pancreatitis. Tirzepatide can also demonstrate efficacy in weight loss, leading to its off-label use for obesity treatment.

Mechanism of Action

Tirzepatide is a synthetic polypeptide dual agonist for GLP-1 and GIP. Tirzepatide, “twincretin,” exhibits distinct characteristics from GLP-1 receptor agonists.[8] The medication comprises 39 amino acids and is an analog of the gastric inhibitory polypeptide. Functionally, tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia. In addition, tirzepatide also increases the levels of adiponectin.

The dual agonism ability decreases hyperglycemia significantly more than GLP-1 agonist agents and reduces the patient’s appetite.[9] Among patients without diabetes, administering tirzepatide 5 to 15 mg once weekly for managing obesity led to remarkable reductions in body weight, ranging from 16.5% to 22.4% over 72 weeks. Post hoc analyses of fasting biomarkers indicated that tirzepatide exhibited more significant improvements in markers of insulin sensitivity and β-cell function.[10]

Pharmacokinetics

Absorption: Tirzepatide has a bioavailability of approximately 80%. The time it takes to reach peak serum levels can range from 8 to 72 hours.

Distribution: The mean steady-state volume of distribution (Vd) of tirzepatide is approximately 10.3 L. Tirzepatide is highly bound to plasma albumin (99%).

Metabolism: When injected, the peptide structure undergoes proteolytic cleavage. In addition, the C20 fatty diacid composition undergoes β-oxidation and amide hydrolysis. Being a modified polyp